The Quantellect read.As of Nov 19, 2026, 6 active firms cover Bicycle Therapeutics Ltd: 3 rate it Buy or better, 3 sit at Neutral, and 0 rate it Sell or worse, a neutral consensus. The target range is very wide, $7.00 to $36.00 (about 5.1x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $14.50 sits 367% above the current $3.10. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.61 next quarter toward $-2.40 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 active firms
Neutral
Strong Buy00%
Buy350%
Neutral350%
Sell00%
Strong Sell00%
Based on 6 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$14.50
+367.0% upside
Average target across 6 active firms as of Nov 19, 2026 vs $3.11 current
Highest Target$36.00
Average Target$14.50
Lowest Target$7.00
Detailed analyst forecasts for BCYC
Showing 1–6 of 6 named analysts shown · 6 active firms in the rating projection
As of Nov 19, 2026, 3 of 6 active firms rate BCYC a Buy (3 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
BCYC EPS & revenue forecast
EPS · NEXT QUARTER
$-0.61
Range $-0.65 – $-0.55 · 3 analysts · -30% YoY
Next period, 3 analysts expect Bicycle Therapeutics Ltd to earn $-0.61 a share (range $-0.65 – $-0.55), versus $-0.87 a year earlier. Full-year consensus is $-2.26, growing to $-2.40 the year after.
REVENUE · NEXT QUARTER
$1.1M
Range $0 – $2.5M · 3 analysts · +20% YoY
Revenue is expected to reach $1.1M (range $0 – $2.5M), +20.4% year-over-year. Full-year consensus is $37.6M, rising to $5.3M next year.
Top analysts covering Bicycle Therapeutics Ltd
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BCYC.
#1
JH
Jeffrey Hung
Morgan Stanley · Rank #10
Neutral
$12.00+286.5% to target
Overall win rate
64%
+ Follow
#2
Leonid Timashev
RBC Capital · Rank #27
Neutral
$5.00+61.0% to target
Overall win rate
52%
+ Follow
#3
SL
Sudan Loganathan
Stephens & Co. · Rank #80
Neutral
$15.00+383.1% to target
Overall win rate
47%
+ Follow
#4
Peter Lawson
Barclays · Rank #89
Buy
$15.00+383.1% to target
Overall win rate
45%
+ Follow
#5
Ami Fadia
Needham · Rank #92
Buy
$14.00+350.9% to target
Overall win rate
46%
+ Follow
BCYC stock forecast FAQ
What is BCYC's average 12-month price target?+
The 6 active firms with a live target average $14.50 for Bicycle Therapeutics Ltd over the next 12 months, ranging from a $36.00 high to a $7.00 low, as of Nov 19, 2026.
Is BCYC stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 6 active firms as of Nov 19, 2026, 3 rate it Buy or Strong Buy, 3 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for BCYC?+
The Street-high target is $36.00 (Oppenheimer), and the Street-low is $7.00 (RBC Capital). The average of all 6 active-firm targets is $14.50.
How many active Wall Street firms cover BCYC?+
6 active firms have a recognized rating on Bicycle Therapeutics Ltd as of Nov 19, 2026, and 6 active firms carry a live 12-month price target.
Who is the most accurate analyst covering BCYC?+
Among analysts who currently cover BCYC, Jeffrey Hung of Morgan Stanley has the strongest overall Quantellect track record (Rank #10). Their current call is Neutral with a $12.00 target.
What is Bicycle Therapeutics Ltd's projected EPS for next quarter?+
The consensus estimate is $-0.61 per share (range $-0.65 – $-0.55) across 3 analysts. Full-year EPS is projected at $-2.26, rising to $-2.40 the following year.
How much revenue is Bicycle Therapeutics Ltd expected to report next quarter?+
Consensus revenue is $1.1M (range $0 – $2.5M). Full-year revenue is projected at $37.6M, growing to $5.3M next year.
Have analysts been upgrading or downgrading BCYC lately?+
As of Nov 19, 2026, 3 of 6 active firms rate BCYC a Buy (3 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BCYC calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.